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Introduction: Timely administration of appropriate antibiotic therapy has been shown to improve outcome in
hospital-acquired pneumonia (HAP). Empirical treatment guidelines tailored to local ecology have been advocated
in antibiotic stewardship programs. We compared a local ecology based algorithm (LEBA) to a surveillance culture
based algorithm (SCBA) in terms of appropriate coverage and spectrum of antimicrobial activity.
Methods: We retrospectively assessed 2 hypothetical empirical antibiotic treatment algorithms for HAP on an existing
high-quality prospectively collected database in a mixed 36-bed tertiary intensive care unit (ICU). Data on consecutive
episodes of microbiologically confirmed HAP were collected over a period of 40 months and divided in a derivation
(1 July 2009 to 31 October 2010) and validation (1 November 2010 until 31 October 2012) cohort. On the derivation
cohort we constructed a LEBA, based on overall observed bacterial resistance patterns, and a SCBA, which targeted
therapy to surveillance culture (SC) in the individual patient. Therapy was directed against pathogens found in respiratory
SC collected two to five days before HAP, and in the absence of these, presence or absence of multi-drug resistant (MDR)
pathogens in other SC dictated broad-spectrum, respectively narrow spectrum antibiotic therapy. Subsequently, LEBA and
SCBA were retrospectively reviewed and compared with actually prescribed antibiotics in the validation cohort.
Results: The first 100 HAP episodes made up the derivation cohort and the subsequent 113 HAP episodes the validation
cohort. Appropriate antibiotic coverage rates by applying LEBA and SCBA were 88.5% and 87.6%, respectively, and did not
differ significantly with respect to appropriateness of the actually prescribed initial therapy (84.1%). SCBA proposed more
narrow spectrum therapy as compared to LEBA and the actually prescribed antimicrobials (P <0.001). SCBA recommended
significantly less combination therapy and carbapenems compared to LEBA (P <0.001). SCBA targeted antibiotics to
recent respiratory SC in 38.1% (43 out of 113 episodes) of HAP; in these cases adequacy was 93% (40 out of 43).
Conclusion: Rates of appropriate antimicrobial coverage were identical in LEBA and SCBA. However, in this setting of
moderate MDR prevalence, the use of SCBA would result in a significant reduction of the use of broad-spectrum drugs
and may be a preferential strategy when implementing antibiotic stewardship programs.* Correspondence: liesbet.debus@ugent.be
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Antibiotic stewardship refers to efforts both made to im-
prove appropriateness of antibiotic prescription and to
reduce antibiotic selection pressure by limiting unneces-
sary use of antibiotics, especially those with a broad
spectrum [1,2]. As hospital-acquired pneumonia (HAP)
is a frequent indication for antibiotic prescription as well
as a manifestation of antibiotic resistance, antibiotic policy
for HAP is an important target area for antibiotic steward-
ship. Early appropriate antibiotic therapy is a major deter-
minant of outcome in HAP: early refers usually to the
time of the initial clinical diagnosis or suspicion of
pneumonia [3-5]. As at this early stage, microbial etiology
is still unknown and potentially multi-drug resistant
(MDR), broad-spectrum antibiotics, often in combination
schemes, are advocated as empirical therapy. As the mi-
crobial and resistance patterns are variable across ICUs,
these empirical schemes have to be matched to the local
situation in order to achieve high rates of appropriate
coverage whilst avoiding unnecessary broad-spectrum an-
tibiotics [6,7]. In addition, algorithms may contribute to
antibiotic stewardship as they assist to rationalize anti-
biotic choices and reduce prescription variability, improve
overall appropriateness and restrain use of certain drug
classes such as carbapenems. As a more controversial
approach, early antibiotic therapy may be guided by
surveillance cultures (SC) to improve its appropriateness
[8-11]. With this approach, antibiotics are essentially
selected in order to cover colonizing pathogens in the
individual patient.
In this study, we developed two algorithms for initial
antibiotic prescription in ICU patients with suspected
HAP. We aimed a) to assess the potential of an algorithm
to aid in antibiotic stewardship in our setting and b) quan-
tify the contribution of SC to antibiotic stewardship
as compared to empirical therapy based upon local
epidemiology.
Materials and methods
Clinical setting and design
This retrospective analysis was conducted at the 14-bed
Medical ICU and the 22-bed Surgical ICU of the Ghent
University Hospital (1,056 beds). With the aid of the
software application, Computer-based Surveillance and
Alerting of infections, Antimicrobial Resistance and
Antibiotic consumption in the ICU (COSARA), all epi-
sodes of pneumonia were registered prospectively from
1 July 2009 to 31 October 2012. COSARA assists the
attending ICU-physician in acquiring an overview of the
various daily collected data related to infection diagnosis
(trends in laboratory values, temperature, oxygenation et
cetera) and treatment. This includes a graphical display
of current and past antibiotic treatments as a timeline
and provides direct links to a real-time copy of thevarious source records. The graphical interface allows
the user to label infectious episodes during daily clinical
rounds and interdisciplinary staff meetings to a prede-
fined list of diagnoses in all patients admitted to the
ICU. As such, the program facilitates the build-up of an
extensive data-warehouse on antibiotic use and infection
in the ICU [12]. During the study period treating physi-
cians were not guided in the choice of the empirical anti-
microbial by treatment algorithms. The Ghent University
Hospital ethics committee approved the study and waived
informed consent as prospective registration did not affect
treatment decisions, and all subsequent analyses were
performed retrospectively on an anonymized database.
Only patients aged 16 years or above were included.
Definition of hospital-acquired pneumonia
Pneumonia was defined to be hospital-acquired if it
occurred 48 h or more after admission to the hospital.
HAP was defined clinically as the presence of new and/
or progressive and persistent pulmonary infiltrates on
the chest radiograph, in combination with two or more
of the following criteria: worsening of oxygenation, in-
crease in purulent tracheobronchial secretions, presence
of fever (≥38.5°C) or hypothermia (≤36°C). Only micro-
biologically confirmed HAP was included: confirmation
consisted of the isolation of a respiratory pathogen with
at least 1+ semiquantitative growth of a good quality
respiratory sample (defined as <3 squamous epithelial
cells per low-power field) obtained within one calendar
day prior or after clinical diagnosis of HAP. In our hospital,
microbiological analysis of respiratory samples routinely
consists of semiquantitative culture of endotracheal aspir-
ate (ETA) in the ventilated patient or sputum in the non-
intubated patient. For logistic reasons, broncho-alveolar
lavage (BAL) is not systematically performed, similarly to
current practice in the majority of European ICUs [13].
We previously found that BAL and ETA had good qualita-
tive and quantitative concordance in a cohort of patients
with suspected ventilator-associated pneumonia (VAP).
Positive and negative predictive values of a semiquan-
titative growth score of 1+ of a pathogen in ETA to
identify the same pathogen in a quantity of at least
104 colony-forming units (CFU)/ml in BAL were 81%
and 87%, respectively [14]. HAP was defined to be
ventilator-associated if at the time of diagnosis, patients
were under mechanical ventilation for 48 h or longer, or
had been extubated for less than 48 h after mechanical
ventilation for at least 2 days.
Development of the algorithms
The collected data were divided into a derivation and a
validation cohort. The first 100 HAP episodes (1 July 2009
to 31 October 2010) made up the derivation cohort for
the development of the local ecology-based algorithm
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(SCBA), both aiming to achieve a minimum of 85%
appropriate coverage rate. For LEBA (Figure 1), we
started from the clinical framework of the revised
American Thoracic Society-Infectious Diseases Society
of America (ATS-IDSA) guidelines and our previously
recorded antimicrobial resistance patterns [4]. Clinical
risk factors for MDR pathogens were defined as prior
antimicrobial therapy during the current hospitalization, a
hospital stay of 5 days or more, and previous hospi-
talization for 2 days or more in the preceding 6 months.
SCBA (Figure 2) combined the same clinical risk factors
for MDR with microbiological information from syste-
matically collected SC. The SC consisted of oral, nasal
and rectal swabs and urinary cultures upon admission,
followed by thrice-weekly urinary and once-weekly oral,
nasal and rectal samples in all patients, as well as thrice-
weekly sputum in the non-intubated patient or ETA in the
ventilated patient. In the case of positive respiratory SC
(oral swabs or respiratory samples) 2 to 5 days before
diagnosis of HAP, the antibiotic with the narrowest
spectrum possible covering this (these) pathogen(s) was
proposed (see also Table 1). In the absence of these, an
alternative algorithm was proposed guided by clinical risk
factors as in LEBA, but with upgrading to include all path-
ogens isolated from other SC collected within the lastCefuroxime
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Appropriateness and spectrum of antimicrobial therapy
We compared rates of appropriateness and spectrum
between LEBA, SCBA and actually prescribed anti-
microbial therapy by the treating physician. Therapy
was considered appropriate when all pathogens involved
in the HAP episode were covered by the antibiotic, or by
at least one component of the antibiotic combination. To
quantify the antimicrobial spectrum, we constructed a
scale ranging from 1 - the most narrow-spectrum of
empirical therapy, lacking antipseudomonal activity -
to 5 - a combination therapy of two or more antibiotic
agents (Table 1). We ranked fluoroquinolones higher than
broad spectrum antipseudomonal β-lactam antibiotics
other than carbapemens, based upon the knowledge
that exposure to fluoroquinolones is particularly asso-
ciated with rapid emergence of MDR pathogens such
as methicillin-resistant Staphylococcus aureus (MRSA)
[15], and with Clostridium difficile-associated diarrhea
[16], and by our aim to preserve the use of fluoroquino-
lones for directed therapy of Stenotrophomonas spp. andHigh riska
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Figure 2 Surveillance culture-based algorithm. aRespiratory pathogen defined as: Acinetobacter spp., Enterobacteriaceae, Haemophilus spp.,
Pseudomonas spp., Staphylococcus aureus, Stenotrophomonas spp., Streptococci. bClinical risk assessment for multi-drug resistant pathogens: high
risk if one of the following characteristics is present: prior antimicrobial therapy; current hospitalization ≥5 days; hospitalization for ≥2 days in the
preceding 6 months. cSeptic shock was defined as systolic arterial blood pressure <90 mmHg or mean arterial blood pressure <65 mmHg despite
adequate fluid resuscitation. SC, surveillance cultures; HAP, hospital-acquired pneumonia; MDR, multi-drug resistant.
Table 1 Scale quantifying the spectrum of the antibiotic
treatment
Step Treatment
1 Non-antipseudomonal penicillins (amoxicillin-clavulanate)
Second generation or third generation non-antipseudomonal
cephalosporins (cefuroxime, ceftriaxone)
Trimethoprim/sulfamethoxazole
2 Antipseudomonal penicillins (piperacillin-tazobactam)
Third generation antipseudomonal cephalosporins (ceftazidime)
3 Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)
4 Antipseudomonal carbapenems (meropenem)
5 Combination therapy of two or more antibiotic agents
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the antimicrobial spectrum was expressed as x steps in ex-
cess to the most narrow-spectrum therapy possible cover-
ing all causative pathogens isolated in the HAP episodes.
Statistics
Continuous variables are described as mean (±standard
deviation) or median (interquartile range) for normal or
non-normal distribution, respectively. To compare paired
proportions the McNemar test for related samples was
used. Differences in medians were checked using the Wil-
coxon signed-rank test. All statistical analyses were per-
formed with SPSS® software (SPSS, version 21, Chicago,
IL, USA). Statistical significance was defined as P <0.05.
Results
All data reported apply to the validation cohort of 113
episodes of HAP, including 52 (46%) episodes of VAP,
Table 2 Pathogens (n = 140) associated with HAP
Pathogen Number of
total
Gram-positive bacteria
Staphylococcus aureus 14 (10.0)
MRSA (5%)
Streptococcus pneumonia 5 (3.6)
Other streptococci 1 (0.7)
Gram-negative bacteria
Enterobacteriaceae 70 (50.0)
Escherichia coli 31 (22.1)
Enterobacter sp. 13 (9.3)
Klebsiella sp. 12 (8.6)
Serratia sp. 6 (4.3)
Morganella morganii 4 (2.9)
Citrobacter sp. 2 (1.4)
Hafnia alvei 1 (0.7)
Proteus sp. 1 (0.7)
ESBL-producing enterobacteriaceae (5.7%)
Non-fermenters 35 (25)
Pseudomonas aeruginosa 27 (19.3)
Ceftazidim resistance (5%)
Carbapenem resistance (6.4%)
Stenotrophomonas maltophilia 5 (3.6)
Acinetobacter baumannii* 3 (2.1)
Other gram-negative bacteria
Haemophilus influenzae 12 (8.6)
Moraxella catarrhalis 3 (2.1)
Total 140
*All Acinetobacter baumannii isolates were third generation cephalosporin-
resistant and carbapenem sensitive. HAP, hospital-acquired pneumonia; MRSA,
methicillin-resistant Staphylococcus aureus; ESBL, extended-spectrum
beta-lactamase producing enterobacteriaceae.
Table 3 Pathogens associated with inadequate empirical
therapy
Pathogen Prescribed therapy LEBA SCBA
Acinetobacter baumannii 3 - 1
Escherichia coli 4 - 2
Enterobacter sp. 2 - -
Klebsiella sp. - - 1
MRSA - 4 3
Pseudomonas aeruginosa 4 3 4
Serratia sp. 2 2 2
Stenotrophomonas maltophilia 3 5 2
Results are presented as number. LEBA, local ecology-based algorithm; SCBA,
surveillance culture-based algorithm; MRSA, methicillin-resistant Staphylococcus
aureus.
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2012 in 104 patients. There was need for subsequent
mechanical ventilation in 39/61 (64%) of the non-VAP
patients. The median age of the patients was 64 years
(54 to 74), and 74% were male. In 99 (87.6%) of the
HAP episodes, clinical risk factors for MDR pathogens
were present: prior antibiotics in 81%, current hospi-
talization for 5 days or more or hospitalization in the
previous 6 months in 82%. Septic shock was present in
23% of the HAP episodes. The length of ICU stay following
diagnosis of HAP was 10 days (6 to 22) when appropriate
antibiotics were administered, 7 days (2 to 16) if the
prescribed antibiotics were inappropriate (P = 0.10). The
overall ICU mortality was 30.1% and did not differ be-
tween patients with or without appropriate antimicrobial
therapy (28.4% versus 38.9%, P = 0.375).
A total of 140 pathogens were isolated, 84% of which
were Gram-negative bacteria (Table 2). HAP was mono-
microbial in 89 (79%) and poly-microbial in 24 (21%)
episodes.
Appropriateness and spectrum of antimicrobial therapy
Appropriate antibiotic therapy was prescribed in 95 (84.1%)
HAP episodes. Antimicrobial choices proposed by LEBA
and SCBA were appropriate in 88.5% and 87.6%, respect-
ively. Paired analysis showed no significant difference in
adequacy for the different strategies (prescribed therapy
versus LEBA: P = 0.33; prescribed therapy versus SCBA:
P = 0.5; LEBA versus SCBA: P = 0.99). Pathogens asso-
ciated with inadequate empirical therapy are detailed in
Table 3.
In significantly more episodes, SCBA proposed antibi-
otics of a narrower spectrum as compared to both the
prescribed therapy and the regimen suggested by LEBA
(P <0.001) (Figure 3). Significantly less combination therapy
was proposed by SCBA (7.1%) in comparison with LEBA
(81.4%) (P <0.001). SCBA recommended carbapenems
in significantly fewer episodes than LEBA (24 (21.2%)
versus 92 (81.4%), respectively (P <0.001)).
Surveillance culture-based algorithm
Respiratory SC sampled 2 to 5 days before HAP onset
were available in 63 episodes (55.8%) of HAP, of which
43 (68%) grew at least one pathogen. As such, SCBA
suggested targeted antimicrobial therapy in 43/113 (38.1%)
of HAP episodes: HAP for which targeted therapy was sug-
gested was ventilator-associated in 72% (31/43), occurred
more than 5 days after ICU admission in 77% (33/43) and
was caused by the following pathogens (n = 53): S. aureus
(6/53, 3 methicillin-susceptible S. aureus and 3 MRSA),
S. pneumonia (1/53), Enterobactereaceae (29/53), P. aeru-
ginosa (10/53), other Gram-negative bacteria (7/53). Recent
respiratory SC accurately predicted all causative pathogens
in 81.4% (35/43) of HAP; SCBA-targeted antimicrobial
38%
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6%
20%
40%
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Figure 3 Evaluation of the spectrum of antimicrobial therapy. LEBA, local ecology-based algorithm; SCBA, surveillance culture-based algorithm.
LEBA: 3 (1.25 to 4) steps in excess; SCBA: 0 (0 to 1) steps in excess; Prescribed therapy: 1 (0 to 2) steps in excess.
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(including those not predicted by SC) in 93% (40/43)
of cases.
In the case of negative or absent respiratory SC 2 to
5 days before start of HAP (n = 70, 61.9%), SCBA took
into account both respiratory SC more than 5 days prior
to infection and non-respiratory SC. In 28/70 (40%)
of these HAP episodes positive SC were available,
leading to upgrading of the proposed empirical therapy in
13/70 HAP (19%) and a switch from inappropriate to
appropriate antibiotic proposals in 10 episodes. By not
upgrading our therapy in these cases our rate of ap-
propriate antibiotic therapy would have dropped from
87.6% to 78.8%.
Discussion
Both guidance by SC as well as the use of ICU-specific
empirical schemes that incorporate local microbiology
data have been shown to increase appropriate empirical
prescription and reduce the use of broad-spectrum anti-
microbials as compared to general guidelines [4,7,8,17-19].
Our study is the first to demonstrate the benefit of SC in
surplus to tailoring guidelines to local susceptibility data.
We found that incorporating results of SC (SCBA) in a
clinical algorithm (LEBA) to help the choice of an em-
pirical antibiotic regimen in suspected HAP would allow
reduction in the use of broad-spectrum antimicrobials for
equal rates of appropriate coverage. In particular, a 60%
decrease in the empirical use of carbapenems would be
attained, which is an important achievement in terms of
antibiotic stewardship. Similarly, as compared to actually
prescribed antibiotics, which were at the discretion of the
attending physician with access to SC results but without
guidance by a treatment algorithm, stricter adherence toSCBA would lead to further constraint of empirical use of
broad-spectrum drugs. We measured the expenditure of
antibiotics in terms of extension of spectrum by ranking
antimicrobial classes along a scale of increasingly broad
antimicrobial coverage. While this scale artificially trans-
lates a complex phenomenon into a simplified score, it
allows some quantification of ecological selection pressure
between different antibiotic schemes.
Two observations underlie the construction of SCBA.
First, previously we found high negative predictive values
of negative SC for the presence of MDR pathogens in
HAP [9], allowing a narrower-spectrum antibiotic even
in patients with clinical risk factors for MDR. Second,
we followed the paradigm that ICU-acquired pneumonia
is often preceded by colonization of the upper and lower
airways by the same pathogen, going through a pos-
sible intermediate stage of ventilator-associated tracheo-
bronchitis [20]. Following Bayes’ theorem, the positive and
negative predictive values of SC were then applied to the
ATS-IDSA guideline-based clinical risk categories for
MDR HAP. Although there are no reports suggesting
resistant micro-organisms cause more septic shock, we
opted for broader therapy in these cases to minimize the
risk of harm caused by inappropriate therapy.
In hospital-acquired infection, narrowing the spectrum
of antibiotic therapy is usually done as de-escalation fol-
lowing an initially broad-spectrum therapy aimed at max-
imal chance for appropriate coverage. However, limiting
antimicrobial therapy upfront may offer several advantages.
First, aminoglycosides and glycopeptides, which carry
an important toxicity profile [21,22], were abandoned
in the SCBA if there were no SC results supporting
their need. A study in patients with pneumonia found
increased mortality in patients who were treated with
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recommendations for combination therapy, as compared
to patients in whom treatment deviated from the recom-
mendations [23]. The authors proposed the toxic effects of
combination antimicrobial therapy as a potential explan-
ation. Second, although prolonged exposure to antibiotic
therapy has been clearly associated with the emergence of
resistance [24], there is no proof that a short course is eco-
logically harmless and devoid of selection pressure. Finally,
there exists a gap between the concept of de-escalation
and what is achieved in practice. In several observational
studies, the authors found rates of de-escalation to be fairly
low [25-27], with lack of an identifiable microbial agent
as the main barrier. SCBA partially circumvents this,
as in case of negative diagnostic cultures and SC, a nar-
rower spectrum empirical therapy, is recommended as
compared to LEBA.
Restricting the number of empirical combination ther-
apies will reduce direct antibiotic costs. On the other
hand one fulltime-equivalent microbiology laboratory
technician is assigned to process SC of all patients ad-
mitted to our 36-bed ICU and the cost for the laboratory
material is estimated at 33 euro per week. However, not
all of this cost is exclusively for surveillance purposes, as
few additional respiratory cultures for diagnostic pur-
poses are required under this SC regime. Additionally, it
can be argued that SC are a cornerstone in infection
control in settings where MDR pathogens are endemic
and that their guidance of antibiotic therapy is only an
added benefit [28,29].
A number of limitations have to be addressed. First,
our study is evidently monocentric and our SCBA is
site-specific. However, the concept of SCBA may be
more universally applicable, as the predictive values of
SC as reported in several recent studies are fairly consist-
ent, provided that SC are regularly and at least twice
weekly sampled [19]. Our SCBA could serve as a template,
which has to be translated into antibiotic recommenda-
tions depending on local ecology and carefully assessed be-
fore implementation. Second, resistance rates are moderate
in our setting and the added value of SC in combination
with guidelines tailored to local susceptibility data has to
be re-evaluated in settings with higher resistance rates. As
targeted antimicrobial therapy was proposed by SCBA in
more than one third of HAP episodes, we suspect that
implementing this algorithm would also lead to reduction
in empirical broad-spectrum combination antibiotic ther-
apy in these high-resistance environments. Third, it would
be safe to regularly test the algorithms in order to match
potentially changing ecology. Fourth, this analysis was per-
formed retrospectively, subsequently the algorithms and
adherence by the treating physicians to the algorithms have
not been evaluated in practice. As such, the performance
of the algorithms may in reality be different from what isanticipated. Finally, our study design does not allow us to
conclude whether an empirical strategy with de-escalation,
as compared to a strategy that is more targeted to coloniz-
ing pathogens translates into a different patient out-
come or microbiological selection pressure.
Conclusion
As compared to an algorithm based upon clinical risk
factors for MDR and adapted to local susceptibility results,
an algorithm with additional guidance from SC could
achieve comparably high rates of appropriate coverage with
the use of fewer broad-spectrum antibiotics. Antibiotic
therapy specifically targeted to respiratory pathogens identi-
fied in recent SC would be possible in 38% of HAP epi-
sodes. SC-guided algorithms may constitute a component
of antibiotic stewardship programs. Additional studies
should be performed in ICU settings with higher levels of
antibiotic resistance.
Key messages
 Addition of surveillance culture results in empirical
antibiotic treatment algorithms for hospital-acquired
pneumonia could restrict the use of broad-spectrum
antimicrobial drugs.
 Targeting empirical treatment to recent respiratory
surveillance cultures could be achieved in more than
one third of hospital-acquired pneumonia.
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